Peptide record

TPDB10851

Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10851
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AFP-GFuse Antifungipept CAFPdb i2APP APD_complete APD_hemolytic Hemolytic2 ToxinPred 3.0
standard
No
A 26-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GIWGTLAKIGIKAVPRVISMLKKKKQ
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C133H235N37O30S1
NDCEHFY
K
2864.62
11.90
7
0
12
+7
0.42
0.112
120.00
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
1.92
3
Residue Composition
number
2
A
1
R
0
N
0
D
0
C
0
E
1
Q
3
G
0
H
4
I
2
L
6
K
1
M
0
F
1
P
1
S
1
T
1
W
0
Y
2
V
Amino Acid Distribution
A: 2 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 3 H: 0 I: 4 L: 2 K: 6 M: 1 F: 0 P: 1 S: 1 T: 1 W: 1 Y: 0 V: 2
Chemical Descriptors
26 reviewed residue count
C133H235N37O30S1 sequence-only estimate (linear, free termini)
2864.62 sequence-only estimate (linear, free termini)
11.90 sequence-only estimate (linear, free termini)
+7 sequence-only estimate (linear, free termini)
0.42 sequence-only estimate (linear, free termini)
0.112 sequence-only estimate (linear, free termini)
Evidence Records 6 records
Evidence 1 Activity

Activity

Antibacterial

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class.
warning: during synthesis, one C-terminal lysine was lost. This synthetic form is referred to as W3-desK in the paper. Diffusion assay: This form is active against Gram+ B. cereus CIP 6624, B. megaterium ATCC 9885, B. stearothermophilus CIP 675, B. subtilis ATCC 6623, E. faecalis CIP 636, L. lactis ssp. cremoris I116, S. pyogenes CIP 561, S. sanguinis CIP 55128, L. ivanovii LMA 94, L. monocytogenes ATCC 15313, M. luteus CIP 5345, S. aureus CIP 677 or LMA, S. epidermidis CIP 53134, Gram- bacteria E. coli CIP 548 or L-, E. cloacae CIP 6085, K. pneumoniae CIP 8291, S. enterica CIP 813, S. marcescens LMA TP, A. faecalis CIP 6723, P. aeruginosa CIP A22, P. putida LMA, and yeast S. cerevisiae LMA 720. Updated 5/2025
Evidence 2 Activity

Activity

Antifungal

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class.
warning: during synthesis, one C-terminal lysine was lost. This synthetic form is referred to as W3-desK in the paper. Diffusion assay: This form is active against Gram+ B. cereus CIP 6624, B. megaterium ATCC 9885, B. stearothermophilus CIP 675, B. subtilis ATCC 6623, E. faecalis CIP 636, L. lactis ssp. cremoris I116, S. pyogenes CIP 561, S. sanguinis CIP 55128, L. ivanovii LMA 94, L. monocytogenes ATCC 15313, M. luteus CIP 5345, S. aureus CIP 677 or LMA, S. epidermidis CIP 53134, Gram- bacteria E. coli CIP 548 or L-, E. cloacae CIP 6085, K. pneumoniae CIP 8291, S. enterica CIP 813, S. marcescens LMA TP, A. faecalis CIP 6723, P. aeruginosa CIP A22, P. putida LMA, and yeast S. cerevisiae LMA 720. Updated 5/2025
Evidence 3 Activity

Activity

Antiparasitic

Source & Reference

DRAMP

Other

warning: during synthesis, one C-terminal lysine was lost. This synthetic form is referred to as W3-desK in the paper. Diffusion assay: This form is active against Gram+ B. cereus CIP 6624, B. megaterium ATCC 9885, B. stearothermophilus CIP 675, B. subtilis ATCC 6623, E. faecalis CIP 636, L. lactis ssp. cremoris I116, S. pyogenes CIP 561, S. sanguinis CIP 55128, L. ivanovii LMA 94, L. monocytogenes ATCC 15313, M. luteus CIP 5345, S. aureus CIP 677 or LMA, S. epidermidis CIP 53134, Gram- bacteria E. coli CIP 548 or L-, E. cloacae CIP 6085, K. pneumoniae CIP 8291, S. enterica CIP 813, S. marcescens LMA TP, A. faecalis CIP 6723, P. aeruginosa CIP A22, P. putida LMA, and yeast S. cerevisiae LMA 720. Updated 5/2025
Evidence 4 Activity

Activity

Hemolysis
[Ref.11279030]1mm in test condition against horse erythrocytes (A 12-ml sample of blood agar medium was supplemented with 1 ml of sheep or horse erythrocytes. Wells 5 mm in diameter were filled with 20 µl of the peptide solution and placed overnight at 4℃ to allow the diffusion of the hemolytic agent)

Target

horse erythrocytes

Source & Reference

APD_complete APD_hemolytic
DRAMP4
J. Biol. Chem. 2001 276: 17823-17829.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.
Evidence 5 Activity

Activity

Toxicity
Hemolytic
Hemolytic_activity: [Ref.11279030]1mm in test condition against horse erythrocytes (A 12-ml sample of blood agar medium was supplemented with 1 ml of sheep or horse erythrocytes. Wells 5 mm in diameter were filled with 20 µl of the peptide solution and placed overnight at 4℃ to allow the diffusion of the hemolytic agent)

Target

erythrocytes

Source & Reference

NA
DRAMP
J. Biol. Chem. 2001 276: 17823-17829.
Evidence 6 Hemolysis

Activity

[Ref.11279030]1mm in test condition against horse erythrocytes (A 12-ml sample of blood agar medium was supplemented with 1 ml of sheep or horse erythrocytes. Wells 5 mm in diameter were filled with 20 µl of the peptide solution and placed overnight at 4℃ to allow the diffusion of the hemolytic agent)
Hemolysis

Target

horse erythrocytes

Source & Reference

APD_complete APD_hemolytic
J. Biol. Chem. 2001 276: 17823-17829.
DRAMP4
APD_complete APD_hemolytic